Diabetic Neuropathy Treatment Market Research Report - Global Forecast till 2027

Global Diabetic Neuropathy Treatment Market Research Report: By Disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), By Treatment (Drugs, TENS, Others) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2027

ID: MRFR/HC/6887-HCR | February 2021 | Region: Global | 111 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Forecast

Global Diabetic Neuropathy Treatment Market is expected to cross USD 5.80 Billion by 2025 at a CAGR of 5.1%.

Market Synopsis

The number of diabetic neuropathy cases is increasing globally, fueling market growth. Diabetic neuropathy treatment is the second-highest contributor to global disability and an estimated 30% to 40% of people across the globe live with diabetic neuropathy.

Diabetic neuropathy is most common in low- and middle-income countries, and this disorder requires lifelong care to manage.

Market Influencer

The rising prevalence of diabetic disorders and increasing reimbursement offered to patients by health insurance providers.

Market Drivers

  • Growing global geriatric population.

  • Change in lifestyle habits leading to bad posture, which is increasing the prevalence of diabetic neuropathy disorder.

  • Increasing research and development of new drugs to treat diabetic neuropathy disorder.

  • Rising prevalence of diabetic neuropathy. For example, the prevalence of diabetic neuropathy in the fiscal year 2000 to 2030 will reach up to 366 million people in the US.

  • Rising awareness of advanced treatments for diabetic neuropathy.

  • Launch of a new medication to manage the symptoms of chronic diabetic neuropathy.

Market Restraints

  • High treatment costs.

  • Availability of alternative therapies such as traditional medicine and physiotherapy.

  • Need for specialized equipment to diagnose and treat diabetic neuropathy.


By Disorder

  • Peripheral Neuropathy: The largest segment of the market, peripheral neuropathy afflicts almost 1% of the entire global population and is three times as likely to afflict women than men.

  • Autonomic Neuropathy: This disorder generally afflicts elderly people. As of 2018, about 23 million people in the US had autonomic neuropathy and over a quarter of those afflicted could not perform daily activities.

  • Proximal Neuropathy: It is a rare type of nerve damage that occurs in hip, buttock, or thigh. It typically affects one side of the body and rarely spreads to the other side of the body. About 50% of patients suffering from diabetes have proximal neuropathy.

  • Focal Neuropathy: This focal neuropathy disorder afflicts roughly 3 out of every ten individuals who have diabetes with over 100 million people affected globally.

By Treatment

  • Drugs: The fastest-growing segment of the market, drugs are most widely used for the treatment of diabetic neuropathy. A rise in the number of FDA approvals for drugs to treat diabetic neuropathy is a key factor for the growth of the segment.

  • Transcutaneous Electrical Nerve Stimulation (TENS): The largest segment, TENS is the preferred treatment for many diabetic neuropathies as they reduce inflammation and suppress immune system activity.

  • Others: The other segment includes physiotherapy and electroacupuncture and various other treatment options for diabetic neuropathy.

By End-User

  • Hospitals and Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with diabetic neuropathy. Growing awareness and increasing efficiency of diabetic neuropathy treatment are projected to drive the growth of this segment during the forecast period.

  • Retail Pharmacy: A small segment. This center provides immediate pain relief and rudimentary drugs for diabetic neuropathy.

  • Online Pharmacy: Various drugs are used for the treatment of diabetic neuropathy which can be easily available in online pharmacy.

  • Others: This segment includes home care and senior citizen centers.

By Region

  • Americas: The largest regional market. The prevalence of diabetic neuropathy is high in the Americas. The region also has a well-established healthcare industry. Out of the entire population, around 72.2% people in the US were suffering from diabetic neuropathy in 2017.

  • Europe: An increasing geriatric population is leading to a rise in the number of diabetic neuropathy disorder cases.

  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people afflicted with diabetic neuropathy due to bad posture brought on by lifestyle changes, aging, and genetic predisposition. Diabetic neuropathy is an increasing problem in Asia. Approximately 4000 patients were diagnosed with diabetic neuropathy in Korea in 2017, whereas in Japan, around 298 people were diagnosed with diabetic neuropathy in 2017.

  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.

Key Players

  • Abbott Laboratories (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Eli Lilly and Company (US)

  • Johnson & Johnson (US)

  • GlaxoSmithKline Plc (UK)

  • Lupin Limited (India)

  • Glenmark Pharmaceuticals Limited (India)

  • Depomed, Inc. (US)

  • Astellas Pharma Inc (Japan)

  • Pfizer Inc (US)

  • MEDA Pharma GmBH & Co. KG (Germany)

  • Others

Frequently Asked Questions (FAQ) :

Diabetic neuropathy treatment market was valued at USD 5.8 billion in 2018.

The global market is expected to exhibit a strong 5.1% CAGR over the forecast period from 2019 to 2025.

The growing prevalence of diabetes is the major driver for the market.

The Americas are the leading regional market for diabetic neuropathy treatment due to the growing prevalence of diabetes in the region.

Leading players in the market include Abbott, Astellas Pharma, and Pfizer, among others.

This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.